PDgrastim (filgrastim biosimilar) / Pooyesh Darou - LARVOL DELTA

Effect of culture media and fermentation process on the refolding and purification of rh-GCSF. (PubMed, Protein Expr Purif) - "The purified samples were compared to Neupogen® and PDgrastim reference standards using Western blotting, size exclusion chromatography, and reverse-phase high-performance liquid chromatography. The analysis confirmed that all proteins were correctly refolded and exhibited a purity exceeding 90 % after purification. The highest protein recovery percentage and purity of rh-GCSF with the lowest endotoxin content was achieved using M9 media in fed-batch culture."

Journal • Hematological Disorders • Neutropenia

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial. (PubMed, BMC Cancer) - "It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia."

Adverse events • Clinical • Head-to-Head • Journal • Breast Cancer • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product. (PubMed, Pharm Res) - "Except for the deviating specific activities of the two copy filgrastim products, we found no substantial differences in product quality between the filgrastim products studied."

Journal